Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr. Reddy's Laboratories Ltd. closed 8.46% below its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

Dr. Reddy's Laboratories Ltd. closed 9.41% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Dr Reddy’s Laboratories ( ($RDY) ) has issued an update. On July 23, 2025, Dr. Reddy’s Laboratories announced its financial results for the ...

Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...

Best case scenario, Semaglutide can garner $500 million sales in FY27, HSBC said. It added that Dr Reddy's will be among the ...

Dr Reddy's Laboratories Ltd.'s consolidated net profit rose 1.8% in the first quarter of fiscal 2026, missing analysts' estimates. The pharmaceutical company posted a bottom line of Rs 1,418 crore, ...

Pharmaceutical major Dr. Reddys Laboratories reported its financial results for the first quarter (Q1) of FY26 on Thursday, ...